at 406
Small moleculeexperimental
Clinical trial activity
5 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2010 (NCT01078649)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Inhibitor of apoptosis protein 3INHIBITOR
XIAP inhibitor
- cIAP1/cIAP2INHIBITOR
cIAP1/cIAP2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- at 406
- at-406
- at-406
- at-406
- at406 cpd
- debio1143
- debio 1143
- debio 1143
- n-benzhydryl-5-(2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo(1,2-a)(1,5)diazocine-8-carboxamide
- sm 406
- sm-406
- sm406 cpd
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03270176 | Phase 1 | Oct 10, 2017 | Debiopharm |
| NCT02022098 | N/A | Oct 1, 2013 | Debiopharm |
| NCT01930292 | Phase 1 | Apr 1, 2013 | Debiopharm, University of Toulouse |
| NCT01265199 | Phase 1 | Feb 1, 2011 | Ascenta Therapeutics, The Leukemia and Lymphoma Society |
| NCT01078649 | Phase 1 | Feb 1, 2010 | Debiopharm |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Debiopharm | For profit | 4 | 4 | 2 | 2010 |
| Ascenta Therapeutics | For profit | 1 | 1 | 1 | 2011 |
| The Leukemia and Lymphoma Society | Academic/Hospital | 1 | 0 | 1 | 2011 |
| University of Toulouse | Academic/Hospital | 1 | 0 | 1 | 2013 |
4 organizations
Page 1 / 1